컨텐츠 내용을 수정할 수 있습니다
Hematologic cancers arise from blood-forming or immune cells. Nursing care centers on the consequences of bone marrow failure (infection, bleeding, anemia), the toxicity of treatment, and oncologic emergencies.
Leukemia — malignant white blood cell precursors multiply in the bone marrow, crowd out normal cells, and spill into the blood. Result: anemia (fatigue), neutropenia (infection — the leading cause of death), and thrombocytopenia (bleeding), even when the total WBC count is high.
| Type | Key features |
|---|---|
| Acute myeloid leukemia (AML) | Most common acute leukemia in adults; rapid onset. Acute promyelocytic leukemia (APL) is a subtype with a high risk of DIC and early bleeding death |
| Acute lymphoblastic leukemia (ALL) | Most common childhood cancer; also occurs in adults. Tends to spread to the central nervous system (CNS) and testes |
| Chronic myeloid leukemia (CML) | Philadelphia chromosome — translocation t(9;22) creating the BCR-ABL fusion gene; chronic phase can progress to blast crisis. Very high WBC, splenomegaly |
| Chronic lymphocytic leukemia (CLL) | Most common leukemia in older adults in Western countries; slow; lymphocytosis, lymphadenopathy; often found on routine blood tests |
Risk factors: ionizing radiation, benzene, prior chemotherapy, smoking (AML), Down syndrome and other genetic conditions.
Lymphoma — cancer of lymphocytes, usually beginning in lymph nodes.
Multiple myeloma — cancer of plasma cells in the marrow producing an abnormal monoclonal protein (M-protein). Plasma cells activate osteoclasts, causing lytic bone lesions. Remember CRAB: hyperCalcemia, Renal impairment, Anemia, Bone lesions.
| Test | Key finding |
|---|---|
| CBC with differential, peripheral smear | Cytopenias; blasts in acute leukemia; lymphocytosis in CLL; high WBC with all maturation stages in CML |
| Bone marrow aspiration and biopsy | Confirms leukemia (acute leukemia usually ≥ 20% blasts), myeloma (clonal plasma cells), and marrow involvement by lymphoma |
| Flow cytometry, cytogenetics, molecular tests | Subtype and prognosis; Philadelphia chromosome/BCR-ABL is specific for CML (also found in some ALL) |
| Excisional lymph node biopsy | Diagnoses lymphoma (Reed–Sternberg cells in Hodgkin) |
| PET-CT | Lymphoma staging and response |
| Lumbar puncture | CNS involvement (ALL, some lymphomas) |
| Serum/urine protein electrophoresis, serum free light chains | M-protein, Bence Jones protein in myeloma |
| Calcium, creatinine, uric acid, potassium, phosphate, LDH | Kidney function, tumor lysis risk, tumor burden |
| Coagulation studies (PT, aPTT, fibrinogen, D-dimer) | DIC, especially in APL |
Principles: combination chemotherapy in phases (induction → consolidation → maintenance for ALL), targeted drugs, immunotherapy, radiation, and hematopoietic stem cell transplant (HSCT).
| Disease | Standard approach |
|---|---|
| AML | Intensive induction chemotherapy, then consolidation or allogeneic HSCT; less-intensive regimens (e.g., venetoclax with azacitidine) for older or frail clients. Antifungal prophylaxis during induction |
| APL | All-trans retinoic acid (ATRA) plus arsenic trioxide — highly curable; treat coagulopathy urgently |
| ALL | Multiphase chemotherapy; CNS prophylaxis with intrathecal chemotherapy (e.g., methotrexate); a tyrosine kinase inhibitor for Philadelphia-positive ALL; blinatumomab or CAR-T cell therapy for relapse |
| CML | Oral tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib) — most clients achieve near-normal life expectancy |
| CLL | Watchful waiting while asymptomatic and early stage; treat when symptomatic or progressive — BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) or venetoclax-based therapy |
| Hodgkin lymphoma | ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) ± radiation; for advanced disease newer regimens replace bleomycin with brentuximab vedotin or nivolumab |
| DLBCL | R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or a similar rituximab-based regimen |
| Multiple myeloma | Combinations such as daratumumab, bortezomib, lenalidomide, dexamethasone; autologous HSCT; bone-protecting agents |
| Drug | Key toxicities and monitoring |
|---|---|
| Doxorubicin | Cardiotoxicity (cumulative dose) — baseline and follow-up echocardiogram; vesicant; red urine for 1–2 days |
| Bleomycin | Pulmonary toxicity / fibrosis — baseline and serial pulmonary function tests; report cough or exertional dyspnea; caution with high oxygen concentrations |
| Vincristine, vinblastine | Vesicants; fatal if given intrathecally. Vincristine: peripheral neuropathy, constipation, paralytic ileus |
| Cyclophosphamide | Hemorrhagic cystitis — hydration, frequent voiding, mesna with high doses |
| Rituximab | Infusion reactions (most common with the first infusion) — premedicate, start slowly, titrate. Screen for hepatitis B before starting (reactivation) |
| ATRA / arsenic trioxide | Differentiation syndrome (fever, dyspnea, pulmonary infiltrates, weight gain, hypotension) — report; treated with dexamethasone. Arsenic: QT prolongation — ECG, keep K⁺ and Mg²⁺ normal. Both teratogenic |
| Imatinib and other TKIs | Fluid retention, edema, muscle cramps, nausea, myelosuppression; dasatinib — pleural effusion; nilotinib — QT prolongation, take on an empty stomach |
| Ibrutinib | Atrial fibrillation, bleeding, hypertension |
| Venetoclax | Tumor lysis syndrome — dose ramp-up, hydration, lab monitoring |
| Bortezomib | Peripheral neuropathy; herpes zoster reactivation (antiviral prophylaxis) |
| Lenalidomide | Teratogenic (restricted program); venous thromboembolism — thromboprophylaxis |
| Zoledronic acid / denosumab | Osteonecrosis of the jaw (dental review before starting); zoledronic acid — kidney monitoring; denosumab — hypocalcemia |
| Filgrastim (G-CSF) | Bone pain; rare splenic rupture (left upper quadrant or shoulder pain) |
| CAR-T cells | Cytokine release syndrome (fever, hypotension, hypoxia) and neurotoxicity |
Listed in priority order.
| Complication | What to watch for |
|---|---|
| Neutropenic sepsis | Fever, hypotension, tachycardia, altered mental status |
| Disseminated intravascular coagulation (APL) | Oozing from sites, petechiae, low fibrinogen |
| Tumor lysis syndrome | Dysrhythmias, muscle cramps, oliguria, seizures |
| Invasive fungal pneumonia | Fever, cough, dyspnea, hemoptysis, lung infiltrates |
| Leukostasis (very high WBC) | Dyspnea, hypoxemia, confusion, visual changes |
| Spinal cord compression (myeloma, lymphoma) | New back pain, leg weakness, bladder/bowel changes |
| Superior vena cava syndrome (mediastinal lymphoma) | Facial and arm swelling, distended neck veins, dyspnea |
| Hypercalcemia (myeloma) | Confusion, polyuria, constipation, shortened QT |
다음 이론을 계속 학습하려면 로그인하세요.
로그인하고 계속 학습필기노트, 하이라이터, 메모는 잘 쓰고 있어?
내보내줘운영진이 검토할게요!
마이페이지에서 차단한 회원을 관리할 수 있어요.